Small molecule · Inhibitor of Transmembrane protease, serine 2 (TMPRSS2) · developed by Daewoong Pharmaceutical Co.
Phase 2/3Most advanced trial (none active)
1Registered trials
What is Camostat?
Camostat is an orally bioavailable synthetic serine protease inhibitor that blocks a range of proteases, including trypsin, kallikrein, thrombin and plasmin, and may inhibit the host protease TMPRSS2 that mediates coronavirus cell entry. It is being studied in COVID-19 (coronavirus infection).
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.